A critical review of mathematical models and data used in diabetology

BioMedical Engineering Online

Volumn 5, Issue , 2006, Pages

  Boutayeb, A ^a   Chetouani, A ^a  

^a FACULTÉ DES SCIENCES   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES; DIABETOLOGY; MATRIX ANALYSIS; OPTIMAL CONTROL THEORY;

ALGORITHMS; CONTROL THEORY; INTEGRAL EQUATIONS; MATHEMATICAL MODELS; MATRIX ALGEBRA; ORDINARY DIFFERENTIAL EQUATIONS; PARTIAL DIFFERENTIAL EQUATIONS; RANDOM PROCESSES;

BIOMEDICAL ENGINEERING;

GLUCOSE; INSULIN;

ALGORITHM; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; HUMAN; MATHEMATICAL MODEL; PUBLICATION; STOCHASTIC MODEL; ANIMAL; BIOLOGICAL MODEL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; DRUG EFFECTS; FACTUAL DATABASE; METABOLISM; PANCREAS ISLET BETA CELL; PROCEDURES;

ALGORITHMS; ANIMALS; COMPUTER SIMULATION; DATABASES, FACTUAL; DIABETES MELLITUS; DIAGNOSIS, COMPUTER-ASSISTED; DRUG THERAPY, COMPUTER-ASSISTED; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL;

EID: 33748066947     PISSN: 1475925X     EISSN: 1475925X     Source Type: Journal    
DOI: 10.1186/1475-925X-5-43     Document Type: Article

References (107)

1. The world health report 2003: Today's challenges. [http://www.who.int/ whr/2003/en]. Geneva, World Health Organization
2. International Diabetes Federation: IFD report 2003. [http://www.idf.org/ home/index.cfm].
3. Boutayeb A, Boutayeb S: The burden of non communicable diseases in developing countries. Volume 4. International Journal of Equity in Health; 2005:2.
4. Ratner RE: Type 2 diabetes mellitus: the grand overview. Diabet Med 1998, 14:54-57.
5. Jiwa F: Diabetes in the 1990s-an overview. Stat Bull Metrop Co 1997, 78(1):2-8.
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
7. Bergman RN, Finegood DT, Ader M: Assessment of Insulin Sensitivity in Vivo. Endicrine Reviews 1985, 6(1):45-86.
8. Bergman RN: The minimal model: yesterday, today and tomorrow. In The minmal model Approach and Determination of Glucose Tolerance Volume 7. Edited by: Bergman RN, Lovejoy JC. Boston : Louisiana state university Press; 1997:3-50.
9. Bergman RN: The minimal model of glucose regulation: a biography. In Mathematical Modeling in Nutrition and Health Edited by: Novotny, Green, Boston. Kluwer Academic/Plenum; 2001.
10. Nucci G, Cobelli C: Models of subcatuneous insulin kinetics: a critical review. Computer Methods and Programs in Biomedicine 2000, 62:249-257.
11. Sundell J, Knuuti J: Insulin and myocardial blood flow. Cardiovascular Research 2003, 57(2):312-319.
12. Finegood DT: Application of the minimal model of glucose kinetics. In The minmal model Approach and Determination of Glucose Tolerance Volume 7. Edited by: Bergman RN, Lovejoy JC. Boston: Louisiana state university Press; 1997:51-122.
13. Mari A: Mathematical modelling in glucose metabolism and insulin secretion. Current Opinion Clinical Nutrition Metabolism Care 2002, 5:495-501.
14. Lehmann ED, Deutsch T: Application of computers in diabetes care: a review. II, Computers for decision support and education. Med Inform 1995, 20:303-329.
15. Bellazzi R, Nucci G, Cobelli C: The Subcutaneous Route to Insulin Dependent Diabetes Therapy: Closed-Loop and Partially Closed-Loop Control Strategies for insulin Delivery and Measuring Glucose Concentration. IEEE Engrg Medicine Biol 2001, 20(1):54-64.
16. Parker RS, Doylelll FJ, Peppas NA: The Intraveneous Route to Blood Glucose Control: A Review of Control Algorithms for Noninvasive Monitoring and Regulation in Type 1 Diabetic Patients. IEEE Engineering in Medicine and Biologie 2001, 20(1):65-73.
17. Koschinsky T, Heinemann : Sensors for glucose monitoring: technical and clinical aspects. Diabetes/Metabolism Research and Reviews 2001, 17:113-123.
18. Palerm CCR: Drug Infusion Control: An Extended Direct Model Reference Adaptive Control Strategy. In Ph.D Thesis Volume chap 3-4. Rensselear Polytechnic Institute, Troy, New York; 2003:45-60.
19. Makroglou A, Li J, Kuang Y: Mathematical models and software tools for the glucose-insulin regulatory system and diabetes: an overview. Applied Numerical Mathematics 2006, 56:559-573.
20. Kalergis M, De Grandpre E, Andersons C: The Role of the Glycemic Index in the Prevention and Management of Diabetes: A Review and Discussion. Canadian Journal of Diabetes 2005, 29(1):27-38.
21. Atun R, Gurol-Urganci I: Health expenditure: an 'investment' rather than a cost? International Economics Programme; 2005. IEP XP 05/01.
22. Boutayeb A: The double burden of communicable and non communicable diseases in developing countries : A review. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006, 100:191-199.
23. Himsworth HP, Ker RB: Insulin-sensitive and insulin insensitive types of diabetes millitus. Cli Sci 1939, 4:119-122.
24. Bolie VW: Coefficients of normal blood glucose regulation. J Appl Physiol 1961, 16:783-788.
25. Ackerman E, Gatewood LC, Rosevear JW, Molnar GD: Model studies of blood glucose regulation. Bull Math Biophys 1965, 27:21-24.
26. Della C, Romano MR, Voehhelin MR, Seriam E: On a mathematical model for the analysis of the glucose tolerance curve. Diabetes 1970, 19:145-148.
27. Serge G, Turcogl M, Varcellone G: Modelling blood glucose and insulin kinetics in normal diabetic and obese subjects. Diabetes 1973, 22:94-97.
28. Srinivasan R, Kadish AH, Sridhar R: A mathematical model for the control mechanism of free-fatty acid and glucose metabolism in normal humans. Comp Biomed Res 1970, 3:146-149.
29. Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative Estimation of Insulin Sensitivity. Am J Physiol 1979, 23(6):E667-E677.
30. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C: Quantitaive Estimation of beta cell sensitivity to glucose in the intact organism: a Minimal Model of Insulin kinetics in the Dog. Diabetes 1980, 29:979-990.
31. Bergman RN, Bowden CR, Cobelli C: The Minimal Model approach to quantification of factors controlling glucose disposal in man. In Carbohydrate Metabolism Volume chap 13. Edited by: Cobelli, Bergman. John Wiley & Sons Ltd; 1981:269-293.
32. Cobelli C, Mari A: Validation of mathematical models complex endocrine-metabomism systems. A case study on a model of glucose regulation. Med & Biot Eng & Comput 1983, 21:390-399.
33. Cobelli C, Nucci G, del Prato S: A physiological simulation model of the glucose-insulin system in type 1 diabetes. Diabetes, Nutrition & Metabolism 1998, 11(1):78-80.
34. Derouich M, Boutayeb A: The effect of physical exercise on the dynamics of glucose and insulin. Journal of Biomechanics 2002, 35:911-917.
35. Bergman RN: Pathogenesis and prediction of diabetes mellitus: lessons from integrative physiology. Mount Sinai J Medicine 2002, 60:280-290.
36. De Gaetano A, Arino, O: Mathematical Modelling of the Intravenous Glucose Tolerance Test. J Math Biol 2000, 40:136-168.
37. De Gaetano A, Arino, O: A statistical approach to the determination of stability for dynamical systems modelling physiological processes. Math Comput Modelling 2000, 31:41-51.
38. Li J, Kuang Y, Li B: Analysis of IVGTT Glucose-Insulin Interaction Models with time delay. Discrete and Continous Dynamical Systems Series B 2000, 1(1):103-124.
39. Mukhopadhyay A, De Gaetano A, Arino O: Modelling the intravenous glucose tolerance test: A global study for single-distributed-delay model. Discrete and Continous Dynamical Systems Series B 2004, 4(2):407-417.
40. Cobelli C, Thomaseth K: Optimal input design for identification of compartimental models : theory and applications to a model of glucose kinetics. Mathematical Biosciences 1985, 77:267-270.
41. Cobelli C, Thomaseth K: The minimal model of glucose disappearence : optimal input studies. Math Biosciences 1987, 83:127-130.
42. Cobelli C, Thomaseth K: An optimalality of the impulse input for linear system identification. Math Biosciences 1988, 89:127-129.
43. Cobelli C, Thomaseth K: Optimal equidose inputs and role of measurement error for estimating the parameters of a compartmental model of glucose kinetics from continuous and discrete time optimal examples. Math Biosciences 89:135-137.
44. Lam ZH, Hwang KS, Lee JY, Chase JG, Walker GC: Active insulin infusion using optimal and derivative weighted control. Medical engineering physics 2002, 24:663-672.
45. Salam J, Charles MA: Devices for insulin administration. Diabetes care 1999, 13:955-979.
46. Lehman ED, Deutsch T: A physiological model of glucose insulin interaction in type 1 diabetes mellitus. J Biomed Eng 1992, 14:235-242.
47. Lehman ED, Deutsch T, Rondsari AV, Carson ER, Sonksen PH: Validation of a metabolic prototype to assist in the treatment of insulin dependent diabetes mellitus. Volume 18. Med Inform London; 1993:83-101.
48. Shimoda S, Nishida K, Sakakida M, Konno, Y, ishinose K, Uehara M, Nowak T, Shichiri M: Closed-loop subcutaneous isulin infusion algorithm with a short acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Frontiers Med Biol Eng 1997, 8:197-211.
49. Hashiguchi Y, Sakakida M, Nishida K, Uemura T, Kajiwara K, Shichiri M: Development of a miniaturized glucose monitoring system by combining a needle-type glucose sensor with microdialysis sampling method. Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients. diabetes care 1994, 17(5):387-396.
50. Reaven GM, Doberne L, Greenfield MS: Comparaison of insulin secretion and in vivo in-sulin action in non-obese and moderately obese individuals with non-insulin dependent diabetes mellitus. Diabetes 1982, 31:382-388.
51. Andres R, Swerdloff R, Pozefsky T, Coleman D: Manual feedback technique for the control of blood glucose concentration. In Automation in Analytical Chemistry Edited by: Skeggs Jt LT. Mediad Inc, New York; 1966:486-490.
52. Bagust A, Beale S: Deteriorating beta-cell function in type 2 diabetes: a long-term model. Q J Med 2003, 96:281-288.
53. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
54. Levy JC, Matthews DR, Hermans MP: Correct Homeostasis Model Assessment(HOMA) evaluation uses the computer program(letter). Diabetes Care 1998, 20:2191-2192.
55. Bernoulli D: Essai d'une nouvelle analyse de la mortalité causée par la petite vérole et des avantages de l'inoculation pour la prévenir. In mémoire de mathématiques et de physique Edited by: Académie Royale des Sciences. Paris; 1760:1-45.
56. Hethcote HW: A thousand and one epidemic models. In Frontiers in Theoretical Biology Edited by: Levin. 100, Springer-Verlag, Berlin; 1994:504-515. Lecture notes in Biomath
57. Hethcote HW: The Mathematics of Infectious Diseases. SIAM REVIEW 2000, 42(4):599-653.
58. Boutayeb A, Kerfati A: Mathematical models in diabetology modelling. Measurement and Control, C, AMSE 1994, 44:53-63.
59. Boutayeb A, Derouich M: Age structured models for diabetes in East Morocco. Mathematics and Copmuter Simulation 2002, 58:215-229.
60. Boutayeb A, Twizell EH: An age structured model for complications of diabetes mellitus in Morocco. Simulation Modelling Practice and Theory, 2004, 12:77-87.
61. Boutayeb A, Chetouani A: Dynamics of a disabled population in Morocco. Biomedical Engineering Online 2003, 2:2.
62. Boutayeb A, Twizell EH, Achouyab K, Chetouani A: A mathematical model for the burden of diabetes and its complications. Biomedical Engineering Online 2004, 3:20.
63. Boutayeb A, Chetouani A, Achouyab K, Twizell EH: A non-linear population model of diabetes mellitus. Journal of Applied Mathematics and computing 2006, 21:127-139.
64. James RC, Blanchard JF, Campbell D, Clottey C, Osei W, Svenson LW, Noseworthy TW: A model for non-communicable disease surveillance in Canada: the prairie pilot diabetes surveillance system. Chronic Dis Can 2004, 25(1):7-12.
65. Paterson KR: Diabetes epidemiology: present and future. Diabet Med 1999, 16(6):446-7.
66. West KM: Epidemiology of diabetes and its macrovascular complications. Diabetes Care 1979, 2(2):63-4.
67. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. New England Journal of Medicine 1993, 329:977-986.
68. O'Neill S: The UK Prospective Diabetes Study(UKPDS): Questions & Answers. [http://www.diabetes.uk].
69. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbAlc: analysis of glucose profiles and HbAlc in the Diabetes Control and Complications Trial. Diabetes Care 2000, 25:275-278.
70. lc) to the risk of development and progression of retinopathy in the diabetes control complications trial in insulin-dependent diabetes mellitus. Diabetes 1995, 44:968-983.
71. Diabetes Control and Complications Trials Research Group: The absence of a glycemic threshold for the development of long-term complication: the perspective of the diabetes control complications trial in insulin-dependent diabetes mellitus. Diabetes 1996, 45:1289-1298.
72. Diabetes Control and Complications Trials Research Group: Hypoglycemia in the Diabetes Control Complications Trial. Diabetes 1997, 45:271-286.
73. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, (UKPDS Group): The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science 2001, 101:671-679.
74. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR: Risk of Stroke in type 2 diabetes Estimated by the UKPDS risk engine (UKPDS 60). Stroke 2002, 33:776-1781.
75. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR: Risk Factors for myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabete (UKPDS 66). Diabetes Care 2003, 27(1):201-207.
76. Stevens RJ, Stratton IM, Holman RR: Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes (UKPDS 58). Journal of Diabetes Complications 2002, 16(6):371-376.
77. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR, (UKPDS Group): A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The UKPDS Outcomes Model (UKPDS 68). Diabetologia 2004, 47:1747-1759.
78. Klein R, Klein BEK, Moss SE, Davis MD, Demets DL: The Wisconsin epidemiologic study of diabetic retinopathy (WESDR IX): Four year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Archives Ophtalmologic 1989, 107:237-243.
79. Framingham Heart Study [http://www.framingham.com/heart]
80. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002, 356:393-402.
81. The Health Outcomes Prevention Evaluation Study investigators: Effects of angiotension-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. New England Journal Medicine 2000, 342:145-153.
82. The Health Outcomes Prevention Evaluation Study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy. Lancet 2000, 355:253-259.
83. The Health Plan Employer Data and Information Set (HEDIS) [http://www.ncqa.org/Programs/HEDIS]
84. Echantillon national temoin représentant des personnes diabétiques [http://www.invs.sante.fr/publications/entred/ index.html]
85. Multiple Risk Factor Intervention Trial [http://www.gpnotebook.co.uk/ cache/-1777991655.htm]
86. Heart Protection Study (HPS) [http://www.hps.com]
87. Cholesterol and Recurrent Events (CARE) [http://www.care.com]
88. Lewis EJ, Hunsicker LG, Clarke WR, Raymond P, Berl T, Rohde R, Raz I: The effect of angioitensin-converting-enzyme inhibition on diabetic nephropathy antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 1993, 329:1456-1462.
89. Irbesartin in Patients with Type-2 Diabetes and Microalbuminuria Study Group: The effect of Irbesartin on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2001, 345:870-878.
90. Lewis EJ, Hunsicker LG, Clarke WR, Tomas P, Pohl MA, Lewis JB, Ritz E, Alkins RC, Rohde R, Raz I: Renoprotective effect of the angioitensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001, 345:851-860.
91. Colhoun HM, Thomason MJ, Mackeness MI, Moton SM, Betteridge DJ, Durrington PN, Mitman GA, Neil MA, Fuller JH: Design of the Collaborative AtoRvastatin Diabetes Study in patients with type 2 diabetes (CARDS). Diabetes Medicine 2002, 19(3):201-211.
92. American Diabetes Association: Diabetes PHD and Archimedes. [http://www.archimedesmodel.com/pdf/ archimedes-intro_selfguided_press.pdf].
93. Brandeau ML: Modeling complex Medical Decision Problems with Archimedes Model. Annals of Internal Medicine 2005, 143:303-304.
94. Kahn R: Dealing with complexity in clinical diabetes: the value of Archimedes. Diabetes Care 2003, 26(11):3168-3171.
95. Schlessinger L, Eddy DM: Archimedes: A new model simulating health care systems: the mathematical formulation. Journal of Biomedical Informatics 2002, 35(1):37-50.
96. Eddy DM, Schlessinger L: Archimedes: A trial-validated model of diabetes. Diabetes Care 2003, 26(11):3093-3101.
97. Eddy DM, Schlessinger L: Validation of the Archimedes diabetes model. Diabetes Care 2003, 26(11):3102-3110.
98. Herman WH: Diabetes Modeling. Diabetes Care 2003, 26(11):3182-3183.
99. Bagust A, Hopkinson PK, Maier W, Currie CJ: An economic model of the the long-term care burden of type II diabete. Diabetologia 2001, 44:2140-2155.
100. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Mannienen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M: Model of complications of NIDDM II: Model construction and assumptions. Diabetes Care 1997, 20:725-734.
101. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Mannienen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM. II: Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycaemia. Diabetes Care 1997, 20:735-744.
102. Hernando ME, Garcia A, Perdices FJ, Torralba V, Gomez EJ, del Pozo F: Multi-Agent Architecture for the provision of Intelligent Telemedicine Services in Diabetes Management. [http://www.gbt.tfo.upm.es].
103. Brown JB, Russel A, Chan W, Pedula K, Aickin M: The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000, 50(3):S15-S46.
104. Wu H: A case study of type 2 diabetes self-management. Biomedical Engineering Online 2005, 4:4.
105. American Diabetes Association Consensus panel: Guidelines for Computer Modeling of Diabetes and its Complications. (Consensus Statement). Diabetes Care 2004, 27(11):2262-2265.
106. Bagust A, McEwan P: Guidelines for Computer Modeling of Diabetes and its Complications. (Response to American Diabetes Association Consensus Panel). Diabetes Care 2005, 28(11):500.
107. Khan R: Guidelines for Computer Modeling of Diabetes and its Complications.(Response to Bagust and McEwan). Diabetes Care 2005, 28(11):501.